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Summary
DNA methylation, an epigenetic alteration typically occurring early in cancer development, could aid in the
molecular diagnosis of melanoma. We determined technical feasibility for high-throughput DNA-methylation
array-based proﬁling using formalin-ﬁxed parafﬁn-embedded tissues for selection of candidate DNA-methyla-
tion differences between melanomas and nevi. Promoter methylation was evaluated in 27 common benign
nevi and 22 primary invasive melanomas using a 1505 CpG site microarray. Unsupervised hierarchical cluster-
ing distinguished melanomas from nevi; 26 CpG sites in 22 genes were identiﬁed with signiﬁcantly different
methylation levels between melanomas and nevi after adjustment for age, sex, and multiple comparisons and
with b-value differences of ‡0.2. Prediction analysis for microarrays identiﬁed 12 CpG loci that were highly
predictive of melanoma, with area under the receiver operating characteristic curves of >0.95. Of our panel of
22 genes, 14 were statistically signiﬁcant in an independent sample set of 29 nevi (including dysplastic nevi)
and 25 primary invasive melanomas after adjustment for age, sex, and multiple comparisons. This ﬁrst report
of a DNA-methylation signature discriminating melanomas from nevi indicates that DNA methylation appears
promising as an additional tool for enhancing melanoma diagnosis.
Signiﬁcance
Early diagnosis signiﬁcantly improves melanoma survival; yet the histologic diagnosis of melanoma can
be challenging even for experienced pathologists. We established the feasibility of high-throughput DNA-
methylation assays on formalin-ﬁxed parafﬁn-embedded melanocytic tissues, as are typically prepared in
hospital and community-based dermatologic practices. Our study is the ﬁrst to discover a multilocus
DNA-methylation signature that discriminates melanomas from nevi, indicating that DNA methylation
holds promise for molecular diagnosis of melanoma. In addition, knowledge of DNA-methylation differ-
ences between melanomas and nevi could improve our understanding of melanomagenesis, identify
new therapeutic targets, and provide the thrust for detection of occult melanoma in lymph nodes and
blood for staging and monitoring patients.
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Pigment Cell Melanoma Res. 24; 352–360 SHORT COMMUNICATIONFor melanoma, there is a pronounced survival difference
between localized and metastatic disease (98% and 15–
62% 5-year survival, respectively) (ACS, 2010), making
it imperative to diagnose melanoma early. However, his-
tologic diagnosis of melanocytic lesions can be problem-
atic because a single melanocytic lesion may exhibit
conﬂicting diagnostic criteria, making a deﬁnitive diagno-
sis of either a benign nevus or melanoma difﬁcult. One
study reported 15% discordance in the diagnosis of
melanocytic lesions (Shoo et al., 2010). An earlier study
of over 1000 melanocytic lesions reported that an
expert panel found a false positive rate of 14%, misclas-
sifying benign lesions as invasive melanoma, and a false
negative rate of 17%, misclassifying malignant mela-
noma as benign (Veenhuizen et al., 1997). In fact, many
nevi, especially atypical or dysplastic nevi, are difﬁcult to
distinguish from melanoma, even by expert pathologists
(Farmer et al., 1996).
Studies suggest that DNA methylation may provide a
valuable tool, in conjunction with histopathology, for the
molecular diagnostics of melanoma. DNA methylation is
an epigenetic chemical modiﬁcation that does not alter
the sequence code, but can be heritable, and is involved
in the regulation of gene expression (Plass, 2002). The
most common methylation site in mammals is a cyto-
sine located next to a guanosine (CpG). Clusters of
CpGs, referred to as islands, are found in the 5’ regula-
tory and promoter regions of genes (Antequera and
Bird, 1993). Hypermethylation of CpG islands in pro-
moter regions is a common mechanism of tumor sup-
pressor gene silencing in cancer (Herman and Baylin,
2003). Because aberrant promoter methylation with
silencing of tumor suppressor genes has been shown
to occur widely in human melanomas (Furuta et al.,
2004; Hoon et al., 2004) and in histologically premalig-
nant lesions associated with a variety of cancer types
(Fackler et al., 2003), methylation appears promising as
an early diagnostic marker for melanoma.
In this study, we investigated high-throughput array-
based DNA-methylation proﬁling using the Illumina Gold-
enGate methylation Cancer Panel I array, which is
designed to detect methylation at 1505 CpG sites in the
promoters and regulatory regions of 807 cancer-related
genes, to examine technical feasibility as to whether
proﬁling could be accomplished on formalin-ﬁxed tissues
and ‘proof of principle’ that DNA methylations could
distinguish melanomas from nevi. The Cancer Panel I
methylation array was previously validated in side-by-
side comparisons with methylation-speciﬁc PCR and
bisulﬁte sequencing and showed strong correlations
with both methods (Bibikova et al., 2006). After optimiz-
ing conditions for performance of the array, we evalu-
ated array reproducibility and correlation between fresh
versus formalin-ﬁxed specimens. In addition, the effect
of intermixture of melanocytic with non-melanocytic
DNA on methylation proﬁles was examined to estimate
tumor purity necessary for target tissue proﬁling. More-
over, we compared the methylation proﬁles of primary
melanomas to benign nevi.
We initially tested a range of bisulﬁte-treated DNA
quantities (100–500 ng) in the Illumina GoldenGate
methylation Cancer Panel I array, and identiﬁed 200 ng
non-ﬁxed or 250 ng of formalin-ﬁxed bisulﬁte-treated
DNA as the minimum quantity needed to successfully
perform array proﬁling. Such quantities were recover-
able from the FFPE melanocytic tissues in this study.
We found very high reproducibility between non-ﬁxed
cell lines and the same lines that had undergone the
FFPE process. Cell lines were pelleted, formalin-ﬁxed,
and parafﬁn-embedded just as tissue is in the clinical
setting to create FFPE-processed equivalents for cell
lines. Shown in Figure S1A are replicate methylation
array proﬁles of non-formalin-ﬁxed MCF-7 breast tumor
cell DNA, formalin-ﬁxed DNA from the Mel-505 mela-
noma cell line, as well as methylation proﬁles from non-
ﬁxed versus FFPE Mel-505 DNA. Each of these array
replicates produced highly correlated methylation pro-
ﬁles, showing r
2 values of ‡0.98. Methylation analysis
on eight non-ﬁxed cell line replicates, 20 additional non-
ﬁxed and FFPE melanoma cell line pairs, and 14 FFPE
melanoma cell line replicates also yielded highly concor-
dant methylation patterns with a mean r
2 of 0.98, 0.98,
and 0.97, respectively (not shown). These results con-
ﬁrmed that the Illumina GoldenGate Cancer Panel I
methylation array was highly reproducible, and formalin
ﬁxation of the DNA template did not alter the methyla-
tion proﬁle.
In mixing experiments, we estimated the proportion
of melanoma cell line Mel-505 DNA that must be pres-
ent in a cancer⁄normal DNA mixture in order for the
melanoma methylation proﬁle to remain evident. In Fig-
ure S1B, Mel-505 cell line DNA was diluted with
increasing proportions (from 0 to 50%) of DNA from
normal peripheral blood leukocytes (PBLs), and each
mixture was plotted against the proﬁle for pure (100%)
Mel-505 cell line DNA. The Mel-505 cell line proﬁle was
evident even after dilution with up to 30% PBL DNA
(70% Mel-505⁄30% PBL mixture) (r
2 = 0.89), indicating
that a moderate level of contamination of melanocytic
DNA by normal DNA did not signiﬁcantly disrupt the
melanoma methylation pattern. Similarly, FFPE mela-
noma DNA mixed with increasing proportions of FFPE
normal skin DNA maintained melanoma methylation pro-
ﬁles when 70% (r
2 = 0.84) to 80% (r
2 = 0.91) mela-
noma DNA was present (Figure S1C).
In order to compare methylation patterns in nevi and
melanomas, 22 primary invasive melanomas and 27
benign nevi (sample set #1) underwent DNA-methyla-
tion proﬁling using the Illumina GoldenGate Cancer
Panel I and passed ﬁltering criteria. For all comparisons
of Illumina methylation array results, we removed 68
probes that corresponded to CpG sites on the X chro-
mosome and 410 probes that were reported to contain
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unreliable in some samples. Additionally, b-values with a
detection P-value >10
)5 were considered unreliable and
set as missing data points (Marsit et al., 2009); using
this criterion, two nevus samples with more than 25%
missing b-values as well as 39 CpG loci with b-values
missing in more than 20% of samples were excluded
from analysis. The ﬁnal data set consisted of 22 melano-
mas of a variety of histologic subtypes and Breslow
thicknesses (range 0.59–10.0 mm) and 27 common
benign nevi (Table S1) with DNA-methylation proﬁling at
988 CpG loci within 646 genes.
Unsupervised hierarchical clustering was used to
compare b methylation values at CpG loci between
melanomas and nevi. Clustering produced a clear sepa-
ration of melanomas from nevi, with at least two major
clusters each of melanomas and nevi identiﬁed (Fig-
ure 1A), suggesting that the methylation signature of
melanomas is fundamentally distinct from that of the
nevi included in this study. Using class comparison anal-
yses, 168 CpG sites were identiﬁed that differed signiﬁ-
cantly (with adjusted P-values of <0.05) between
melanomas and nevi after Bonferroni correction for mul-
tiple comparisons (Table S2). Seventy-ﬁve of these CpG
sites (in 63 genes) differed by ‡0.2b.
After further adjustment for patient’s age and sex, we
identiﬁed a total of 26 CpG loci in 22 genes that differed
signiﬁcantly between melanomas and nevi, including 19
CpG loci that were signiﬁcantly hypomethylated and 7
CpG loci that were signiﬁcantly hypermethylated in mel-
anoma compared to nevi (Table 1). The heatmap based
on unsupervised clustering of the 26 differentially
methylated CpG loci in melanomas and nevi is shown in
Figure 1B. The genes with loci showing relative hyper-
methylation in melanomas compared with nevi were
KCNK4, GSTM2, TRIP6 (2 CpG sites), FRZB, COL1A2,
and NPR2. The genes with relative hypomethylated loci
in melanoma were CARD15⁄NOD2, KLK10, MPO,
EVI2A, EMR3 (two sites), HLA-DPA1, PTHR1, IL2,
TNFSF8, LAT, PSCA, IFNG, PTHLH, RUNX3 (three CpG
sites), ITK, and CD2. ITK had a second CpG locus that
was signiﬁcantly different between melanomas and nevi
but the b-value difference was <0.2. Five of seven
(71%) hypermethylated CpG loci and 13⁄19 (68%) of
hypomethylated loci were located within gene promot-
ers (according to Illumina annotation). Six of the seven
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Figure 1. Hierarchical clustering of methylation b-values using the Illumina GoldenGate Cancer Panel I array in FFPE nevi and melanomas
from sample set #1. DNA-methylation proﬁles for 22 melanomas and 27 nevi are shown. Columns represent tissue samples; rows represent
CpG loci. Methylation level (b) from 0 (green⁄unmethylated) to 1 (red⁄highly methylated). Missing values are shown in white. (A)
Unsupervised clustering based on 988 CpG sites in 646 genes after ﬁltering (see Methods); probes included autosomal loci and those with a
detection P-value of <0.05. (B) Clusters based on the 26 CpG sites showing signiﬁcantly different methylation b levels between nevi and
melanomas after adjustment for age and sex and Bonferroni correction for multiple comparisons. The upper portion of the heatmap shows
seven CpG loci in six genes exhibiting hypermethylation, and the lower portion shows 19 CpG loci in 16 genes exhibiting hypomethylation
in melanomas compared with nevi.
Conway et al.
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mas were located within CpG islands, while only 2⁄19
(11%) CpG loci showing hypomethylation were within
CpG islands.
Prediction analysis for microarrays (PAM) was carried
out using 988 CpG sites to assess the classiﬁcation of
melanoma and nevus samples by the method of nearest
shrunken centroids (Tibshirani et al., 2002). The PAM
algorithm automatically identiﬁes CpG loci that contrib-
ute most to the melanoma classiﬁcation. Using 10-fold
cross-validation to train the classiﬁer, the optimal shrink-
age threshold was chosen to be 4.28 with 12 CpG loci
required for optimal classiﬁcation. This approach yielded
a zero cross-validation error, with no misclassiﬁcation.
The 12 CpG loci identiﬁed by PAM analysis that provided
the most accurate prediction of melanoma were
RUNX3_P393_R, RUNX3_P247_F, RUNX3_E27_R, COL1
A2_E299_F, MPO_P883_R, TNFSF8_E258_R, CD2_P68_F,
Table 1. Twenty-six CpG loci identiﬁed in sample set #1 exhibiting signiﬁcant promoter methylation differences and b-value differences ‡0.2
between primary melanomas and nevi after adjustment for age, sex, and Bonferroni correction for multiple comparisons
Gene symbol CpG probe Gene description
Sample set 1 Sample set 2
Nevus
mean b
Melanoma
mean b P-value
1 Mean Db AUC AUC
Hypermethylated in melanomas compared with nevi (n = 7)
COL1A2 E299_F Collagen, type I, alpha 2 0.065 0.623 4.07 · 10
)5 )0.558 0.9007 0.6248
FRZB P406_F Frizzled-related protein 0.039 0.374 1.45 · 10
)2 )0.334 0.8986 0.7613***
GSTM2 P453_R Glutathione S-transferase M2 0.145 0.590 6.31 · 10
)3 )0.445 0.9186 0.5731
KCNK4 E3_F Potassium channel, subfamily K,
member 4
0.089 0.479 2.62 · 10
)3 )0.390 0.9057 0.7600
NPR2 P1093_F Natriuretic peptide receptor
B⁄guanylate cyclase B
0.564 0.833 1.78 · 10
)2 )0.269 0.8434 0.6581
TRIP6 P1090_F Thyroid hormone receptor
interactor 6
0.099 0.667 6.30 · 10
)5 )0.568 0.8518 0.7186
TRIP6 P1274_R Thyroid hormone receptor
interactor 6
0.187 0.705 2.71 · 10
)3 )0.518 0.8704 0.5945
Hypomethylated in melanomas compared with nevi (n = 19)
CARD15 ⁄NOD2 P302_R Caspase recruitment domain
family, member 15
0.560 0.114 3.09 · 10
)2 0.446 0.8754 0.7874**
CD2 P68_F CD2 molecule 0.961 0.735 1.26 · 10
)7 0.227 0.9983 0.8414*
EMR3 E61_F EGF-like module-containing
mucin-like hormone
receptor-like 3
0.921 0.485 1.35 · 10
)3 0.436 0.9242 0.9503*
EMR3 P39_R EGF-like module-containing
mucin-like hormone
receptor-like 3
0.920 0.633 2.00 · 10
)3 0.286 0.9259 0.8391*
EV12A P94_R Ecotropic viral integration site 2A 0.783 0.265 1.35 · 10
)3 0.518 0.9592 0.9669*
HLA-DPA1 P28_R Major histocompatibility complex,
class II, DP alpha 1
0.902 0.565 3.32 · 10
)2 0.337 0.9191 0.8400*
IFNG P459_R Interferon gamma 0.915 0.634 7.91 · 10
)9 0.281 0.9630 0.9670*
IL2 P607_R Interleukin 2 0.887 0.590 8.97 · 10
)3 0.297 0.9489 0.8801*
ITK P114_F IL2-inducible T-cell kinase 0.924 0.632 2.68 · 10
)6 0.292 0.9663 0.9076*
KLK10 P268_R Kallikrein-related peptidase 10 0.673 0.257 4.38 · 10
)2 0.417 0.9040 0.6997
LAT E46_F Linker for activation of T cells 0.895 0.540 1.75 · 10
)2 0.355 0.9646 0.8328*
MPO P883_R Myeloperoxidase 0.759 0.165 2.39 · 10
)6 0.593 0.9983 0.8908*
PSCA E359_F Prostate stem cell antigen 0.859 0.658 5.17 · 10
)3 0.201 0.8788 0.6028
PTHLH E251_R Parathyroid hormone-like hormone 0.923 0.602 5.80 · 10
)6 0.322 0.9933 0.8497*
PTHR1 P258_F Parathyroid hormone receptor 1 0.849 0.593 4.56 · 10
)3 0.256 0.8889 0.5848
RUNX3 P393_R Runt-related transcription factor 3 0.967 0.735 3.26 · 10
)8 0.232 1.0000 0.9200*
RUNX3 E27_R Runt-related transcription factor 3 0.960 0.665 6.53 · 10
)8 0.296 0.9983 0.9393*
RUNX3 P247_F Runt-related transcription factor 3 0.964 0.627 1.06 · 10
)8 0.337 1.0000 0.9324*
TNFSF8 E258_R Tumor necrosis factor superfamily,
member 8
0.952 0.599 1.64 · 10
)7 0.353 0.9949 0.9462*
1P-value, nevus mean b, and melanoma mean b were each adjusted for age, sex, and multiple comparisons using Bonferroni correction.
AUC; area under the ROC curve.
P-value signiﬁcant for difference between melanomas and nevi in sample set #2 at the 0.05* or 0.0505** level after adjustment for age, sex,
and multiple comparisons using Bonferroni correction. ***FRZB_P406_F (AUC of 0.7613) was not signiﬁcantly differentially methylated in
sample set #2; however, a different CpG site within the FRZB gene (FRZB_E186_R) was with AUC of 0.8648.
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F, and ITK_E166_R.
The box plots shown in Figure 2A display the distribu-
tion of b-values in nevi and melanomas for the 12 CpG
sites that are highly predictive of melanoma as deter-
mined by PAM analysis. For most CpG loci showing
hypomethylation in melanomas, mean methylation
b-values were uniformly very high (b nearly 1.0) in nevi,
and this methylation was diminished to varying degrees
in melanomas. Among the CpG loci exhibiting hyperme-
thylation in melanomas, FRZB_P406_F and COL1A2_
E299_F were relatively unmethylated in nevi, having
mean b-values near 0.1, but showed considerably higher
methylation in many melanomas, with mean b-values
between 0.6 and 0.7.
Receiver operating characteristic (ROC) curves were
generated showing the sensitivity versus 1-speciﬁcity of
the 12 CpG loci identiﬁed by PAM analysis, which differ-
entiate melanomas from nevi (Figure 2B). The areas
under the ROC curves (AUCs) ranged from 0.89 to 0.90
for the two hypermethylated loci to 0.96–1.00 for the
ten hypomethylated loci. In particular, two of the
RUNX3 probes (RUNX3_P247_F and RUNX3_P393_R)
exhibited 100% sensitivity and 100% speciﬁcity in iden-
tifying melanomas.
We explored the major functions of the 22 differen-
tially methylated genes (with 26 CpG sites) that most
signiﬁcantly distinguished melanomas from nevi and
found associations with several major functions and
pathways including apoptosis, cell cycle, proliferation,
cell adhesion, cell communication and signaling, and
immune response (Table 1). Because the genes were
preselected as part of a cancer panel, only a limited
evaluation could be carried out of functional pathways
using the DAVID Bioinformatics Resources 6.7 (http://
david.abcc.ncifcrf.gov/home.jsp). Of interest, half (11 of
22) of the genes possessed putative immune-related
functions, including roles in T-cell signaling and⁄or natu-
ral killer cell cytotoxicity (IFNG, IL2, ITK, LAT, CD2,
TNFSF8, HLA-DPA1), myeloid–myeloid cell interactions
(EMR3), neutrophil microbicidal activity (MPO), innate
immunity (CARD15⁄NOD2), and NF-jB activation
(TRIP6, CARD15⁄NOD2). Three genes function in thy-
roid (TRIP6) or parathyroid (PTHLH, PTHR1) hormonal
regulation. Several others are tumor suppressor genes
or have previously described or suspected roles in can-
cer cell growth, cell adhesion, or apoptosis (RUNX3,
FRZB, TNFSF8, KLK10, PSCA, COL1A2). Others have
been noted as targets of the polycomb repressor com-
plex in stem cells (RUNX3 and PTHLH from the 26 CpG
site list, and RARA, HOXA11, GABRA5, LOX, and PGR
from the 75 CpG site list) (Lee et al., 2006a; O’Riain
et al., 2009).
A second independent set of 25 melanomas and 29
nevi (sample set #2) were tested for DNA methylation
using the Illumina GoldenGate Cancer Panel I and
passed ﬁltering criteria (Table S1). The melanomas were
of a variety of histologic subtypes and ranged in Bre-
slow thickness from 0.42 to 10.75 mm. The majority of
nevi (21 of 29) had varying degrees of histologic atypia.
Of our panel of 22 genes identiﬁed through analysis of
sample set #1, 14 were also statistically signiﬁcant for
differential methylation in sample set #2 after Bonferroni
correction and adjustment for age and sex (Table 1).
These genes were CARD15, CD2, EMR3 (two CpG
loci), EVI2A, FRZB, HLA-DPA1, IFNG, IL2, ITK, LAT,
MPO, PTHLH, RUNX3 (three CpG loci), and TNFSF8.I t
should be noted that the FRZB_E186 CpG locus rather
than FRZB_P406 was signiﬁcantly differentially methy-
lated in sample set #2. The AUCs for CpG sites within
these genes remained high in sample set #2, ranging
from 0.79 to 0.97.
We found that high-throughput DNA-methylation
array proﬁling was feasible for FFPE melanoctyic
lesions and approximately 250 ng of bisulﬁte-treated
DNA and 70% tumor DNA purity were necessary to
achieve methylation array results representative of
melanocytic target DNA. We identiﬁed 168 differen-
tially methylated CpG loci that signiﬁcantly distinguish
melanomas from nevi after adjusting for multiple com-
parisons; 75 of these CpG loci had mean b differ-
ences of at least 0.2, making the differential
methylation at these loci robust. Further adjustment
for age and sex identiﬁed 26 differentially methylated
CpG sites in 22 genes. Six of these genes exhibited
hypermethylation, while 16 genes showed hypomethy-
lation in melanomas compared with nevi. Each of
these CpG loci had high sensitivity and speciﬁcity for
melanoma diagnosis, with AUCs ranging from 0.84 to
1.0. In PAM analyses, 12 CpG sites in nine genes
provided the most accurate discrimination of melano-
mas from nevi, with no misclassiﬁcation.
Of the 22 genes identiﬁed, 14 (with 16 CpG
loci) were signiﬁcantly differentially methylated in an
independent data set including dysplastic nevi after
adjustment for age, sex, and multiple comparisons.
Only one other study has reported performance of
the Illumina Cancer Panel I array on formalin-ﬁxed com-
pared with non-ﬁxed tissues. In this study, comparison
between matched FFPE and frozen surgical pathology
replicates of follicular lymphomas and follicular hyper-
plasias showed high correlation (r
2 > 0.95) (Killian et al.,
2009), similar to our results using fresh and FFPE pre-
pared melanoma cell lines. We provide additional data
regarding array performance by performing a ‘dose–
response curve’ for detection of tumor DNA methyla-
tion in the presence of non-tumor DNA, and we iden-
tify 70% tumor DNA as a lower limit of purity to
obtain proﬁles representative of the target DNA. We
conclude that samples with higher percentages non-
melanocytic tissue components should be enriched to
this level by selective procurement of tumor cells
using manual or laser capture microdissection before
array proﬁling.
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Figure 2. CpG loci that predict melanoma
identiﬁed by PAM analysis in sample set
#1. (A) Box plots of methylation b levels in
the 12 CpG loci identiﬁed by PAM analysis
as being predictive of melanoma. CpG loci
shown differed by ‡0.2 mean b between
melanomas (M) and nevi (N), except for
ITK_P114_F. Each box plot shows the
median b-value (dark bar within box), the
interquartile range (IQR = Q3)Q1) (outer
boundaries of box). The whiskers (broken
line) cover (Q1)1.5IQR, Q3 + 1.5IQR).
Additional information on mean b-values
for nevi and melanomas, differences in
mean b-values, and P-values adjusted for
age, sex, and multiple comparisons using
Bonferroni correction are given in Table 1.
(B) ROC curves showing the sensitivity
versus 1-speciﬁcity of the 12 CpG loci
identiﬁed by PAM that predict melanoma.
Sensitivity, the true positive rate, is shown
along the y-axis, while 1-speciﬁcity, or the
false positive rate, is shown along the
x-axis. The calculated AUC is given for
each plot in rank order beginning with
highest AUC.
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methylated in melanomas relative to nevi have previ-
ously been examined for promoter methylation in
melanocytic lesions. Among our panel of 26 CpG loci,
Muthusamy et al. (2006) were the ﬁrst to report that
COL1A2 was methylated in 80% of melanomas. Subse-
quently, Koga et al. (2009) reported that COL1A2 was
hypermethylated in 50% and 69% of early and
advanced stage melanomas, respectively, but not in
nevi or normal skin. From our marker panel of 75 CpG
loci with b-value differences of ‡0.2, Liu et al. (2008)
found that TNFSF10D and LOX were methylated in
80% and 50%, respectively, of melanomas.
Interestingly, among our panel of 26 markers, 15 of
19 CpG loci exhibiting relative hypomethylation in mela-
nomas showed uniformly high and nearly complete
methylation in nevi. For example, three CpG loci in the
transcription factor RUNX3 showed nearly complete
methylation in nevi. RUNX3 was previously reported to
be hypermethylated in 23% of melanoma cell lines
(Furuta et al., 2004) but only infrequently in 4% of pri-
mary melanomas (Kitago et al., 2009), but nevi were not
examined in this study, making it unclear whether
RUNX3 methylation levels were relatively increased or
decreased with the acquisition of malignancy. RUNX3
has been considered a tumor suppressor gene, exhibit-
ing both hypermethylation and reduced expression in
gastric and colon cancers (Subramaniam et al., 2009).
However, recent studies suggest that RUNX3 may have
both tumor suppressor and oncogenic properties
depending on the cellular context (Chuang and Ito,
2010) and may function as an oncogene in basal cell
carcinomas (Salto-Tellez et al., 2006) and head and neck
cancers (Tsunematsu et al., 2009).
Among our panel of 75 markers, SYK was found to
be less methylated in melanomas compared with nevi.
Muthusamy et al. (2006) ﬁrst reported SYK to be methy-
lated in 30% of melanoma tumors, and a subsequent
study conﬁrmed this ﬁnding (Liu et al., 2008). These
previous results are not inconsistent with our study
because we also found melanomas to be partially
methylated; however, nevi were more uniformly and
completely methylated. Several other published studies
conducted array-based or comprehensive methylation
screening of multiple loci in melanomas; however, the
genes examined in these reports were not among those
we found to exhibit differential methylation in melano-
mas compared with nevi (Guan et al., 2003; Tanemura
et al., 2009; Jonsson et al., 2010; Bonazzi et al., 2009;
reviewed in Schinke et al., 2010).
Among the 22 genes with CpG sites that distin-
guished melanomas from nevi, half possess immune-
related functions, with several, including ITK and LAT
(Andreotti et al., 2010), CD2 (Sewell et al., 1986),
TNFSF8 (Kennedy et al., 2006), IFNG (Lee et al., 2006b),
and IL2 (Kallies, 2008) operating in T-cell regulatory path-
ways. Other immune-related genes identiﬁed have
reported functions in myeloid–myeloid cell interactions
(EMR3) (Stacey et al., 2001), neutrophil microbicidal
activity (MPO) (Arnhold and Flemmig, 2010), antigen
recognition by T cells (HLA-DPA1) (Lombardi et al.,
2001), innate immunity (CARD15⁄NOD2) (Strober et al.,
2006), NF-jB activation (TRIP6) (Chastre et al., 2009;
Li et al., 2005), or interferon pathways (PSCA) (Marra
et al., 2010). Moreover, as a transcription factor, RUNX3
is important in the development and maturation of
immune cells, including T cells (Wong et al., 2010) and
thus could be involved in the alterations in immune
gene promoter methylation observed between melano-
mas and nevi. The discovery of altered methylation in
T-cell regulatory and other immune genes in melanomas
is not surprising because previous studies have shown
that these tumors often stimulate a signiﬁcant host
immune response (Anichini et al., 2004; Hussein, 2005).
Further study will be needed to determine whether the
differentially methylated immune-related genes are
expressed in melanoma cells or are localized to inﬁltrat-
ing lymphocytes.
Our tissue sets of melanomas included a spectrum of
histologic types, including superﬁcial spreading, nodular,
lentigo maligna, acral lentiginous, spindle cell, and
unclassiﬁable melanomas, indicating that certain
DNA-methylation differences may be consistent across
subtypes. The melanomas also had a wide range of
Breslow thicknesses and were from a variety of
anatomic sites that would have received varying
degrees of sun exposure. In sample set #1, the nevi
tested were chosen to be unequivocally benign by
standard histologic criteria, with only one displaying
slight atypia. In an independent set of melanomas and
nevi that included benign dysplastic nevi (sample set #2),
many of the same genes remained signiﬁcant for differ-
ential methylation.
Our nevus tissues did not include Spitz nevi or Spit-
zoid melanomas, which can be very challenging for
pathologists to diagnose (Barnhill et al., 1999); there-
fore, it will be important to determine whether our puta-
tive melanoma-speciﬁc methylation loci also distinguish
Spitz nevi from melanomas. In addition, patients with
melanoma in this study were older (mean age 61 years,
P < 0.0001) than patients with nevus (mean age
29 years), but to address possible confounding because
of age, we controlled for patient’s age and sex in
the models used to identify CpG loci that distinguish
melanomas.
Our work demonstrates technical feasibility for high-
throughput DNA-methylation proﬁling of FFPE melano-
cytic specimens, as are typically prepared in diagnostic
settings. Using this methodology, our study is the ﬁrst
to identify a multilocus DNA-methylation signature that
is highly accurate for discriminating melanomas from
benign nevi, indicating that DNA methylation holds
promise for molecular diagnosis of melanocytic lesions.
Future studies will work toward determining the
Conway et al.
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benign melanocytic lesions, applicability to borderline
lesions, and performance on specimens from a variety
of medical practices and laboratories. Studies examining
whether our results have implications toward the under-
standing of melanogenesis also seem warranted.
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